Sign in or Register   Sign in or Register
  |  

Mouse Anti-MAML2 Recombinant Antibody (4A1) (CBMAB-A5181-LY)

The product is antibody recognizes MAML2. The antibody 4A1 immunoassay techniques such as: WB, ELISA.
See all MAML2 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
4A1
Antibody Isotype
IgG2a, κ
Application
WB, ELISA

Basic Information

Immunogen
MAML2 (NP_115803, 796 a.a. ~ 894 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Specificity
Human
Antibody Isotype
IgG2a, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Purity
> 95% Purity determined by SDS-PAGE.
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
Mastermind Like Transcriptional Coactivator 2
Entrez Gene ID
84441
UniProt ID
Q8IZL2
Alternative Names
DKFZp686N0150; KIAA1819; MAM-3; MAM2; MAM3; MGC176701; MLL-MAML2
Function
Acts as a transcriptional coactivator for NOTCH proteins. Has been shown to amplify NOTCH-induced transcription of HES1. Potentiates activation by NOTCH3 and NOTCH4 more efficiently than MAML1 or MAML3.
Biological Process
Notch signaling pathwayManual Assertion Based On ExperimentIDA:UniProtKB
Positive regulation of transcription by RNA polymerase IIManual Assertion Based On ExperimentIDA:UniProtKB
Positive regulation of transcription of Notch receptor targetManual Assertion Based On ExperimentIBA:GO_Central
Cellular Location
Nucleus speckle
Nuclear, in a punctate manner.
Involvement in disease
A chromosomal aberration involving MAML2 is found in mucoepidermoid carcinomas, benign Warthin tumors and clear cell hidradenomas. Translocation t(11;19)(q21;p13) with CRTC1. The fusion protein consists of the N-terminus of CRTC1 joined to the C-terminus of MAML2. The reciprocal fusion protein consisting of the N-terminus of MAML2 joined to the C-terminus of CRTC1 has been detected in a small number of mucoepidermoid carcinomas.

Wu, F. Y., Yang, R. M., Zhang, H. Y., Zhan, M., Tu, P. H., Fang, Y., ... & Zhao, S. X. (2023). Pathogenic variations in MAML2 and MAMLD1 contribute to congenital hypothyroidism due to dyshormonogenesis by regulating the Notch signalling pathway. Journal of Medical Genetics.

Nakano, S., Okumura, Y., Murase, T., Nagao, T., Kusafuka, K., Urano, M., ... & Inagaki, H. (2022). Salivary mucoepidermoid carcinoma: histological variants, grading systems, CRTC1/3‐MAML2 fusions, and clinicopathological features. Histopathology, 80(4), 729-735.

Fehr, A., Werenicz, S., Trocchi, P., Falk, M., Friedrich, R. E., Stammler, A., ... & Löning, T. (2021). Mucoepidermoid carcinoma of the salivary glands revisited with special reference to histologic grading and CRTC1/3-MAML2 genotyping. Virchows Archiv, 479(5), 975-985.

Chen, Z., Ni, W., Li, J. L., Lin, S., Zhou, X., Sun, Y., ... & Wu, L. (2021). The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma. JCI insight, 6(7).

Okumura, Y., Nakano, S., Murase, T., Ueda, K., Kawakita, D., Nagao, T., ... & Inagaki, H. (2020). Prognostic impact of CRTC1/3‐MAML2 fusions in salivary gland mucoepidermoid carcinoma: A multiinstitutional retrospective study. Cancer science, 111(11), 4195-4204.

Pérez‐de‐Oliveira, M. E., Wagner, V. P., Araújo, A. L. D., Martins, M. D., Santos‐Silva, A. R., Bingle, L., & Vargas, P. A. (2020). Prognostic value of CRTC1‐MAML2 translocation in salivary mucoepidermoid carcinoma: Systematic review and meta‐analysis. Journal of Oral Pathology & Medicine, 49(5), 386-394.

Yan, M., Gilmore, H., & Harbhajanka, A. (2020). Mucoepidermoid carcinoma of the breast with MAML2 rearrangement: a case report and literature review. International Journal of Surgical Pathology, 28(7), 787-792.

Morita, M., Murase, T., Okumura, Y., Ueda, K., Sakamoto, Y., Masaki, A., ... & Inagaki, H. (2020). Clinicopathological significance of EGFR pathway gene mutations and CRTC1/3–MAML2 fusions in salivary gland mucoepidermoid carcinoma. Histopathology, 76(7), 1013-1022.

Bean, G. R., Krings, G., Otis, C. N., Solomon, D. A., García, J. J., van Zante, A., ... & Chen, Y. Y. (2019). CRTC 1–MAML 2 fusion in mucoepidermoid carcinoma of the breast. Histopathology, 74(3), 463-473.

Sekine, S., Kiyono, T., Ryo, E., Ogawa, R., Wakai, S., Ichikawa, H., ... & Mori, T. (2019). Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. The Journal of clinical investigation, 129(9), 3827-3832.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-MAML2 Recombinant Antibody (4A1)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare